Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Aug 14;25(30):4148-4157.
doi: 10.3748/wjg.v25.i30.4148.

Colorectal cancer surveillance in inflammatory bowel disease: Practice guidelines and recent developments

William T Clarke  1 , Joseph D Feuerstein  2
Affiliations
Review

Colorectal cancer surveillance in inflammatory bowel disease: Practice guidelines and recent developments

William T Clarke et al. World J Gastroenterol. .

Abstract

Patients with long-standing inflammatory bowel disease (IBD) involving at least 1/3 of the colon are at increased risk for colorectal cancer (CRC). Advancements in CRC screening and surveillance and improved treatment of IBD has reduced CRC incidence in patients with ulcerative colitis and Crohn's colitis. Most cases of CRC are thought to arise from dysplasia, and recent evidence suggests that the majority of dysplastic lesions in patients with IBD are visible, in part thanks to advancements in high definition colonoscopy and chromoendoscopy. Recent practice guidelines have supported the use of chromoendoscopy with targeted biopsies of visible lesions rather than traditional random biopsies. Endoscopists are encouraged to endoscopically resect visible dysplasia and only recommend surgery when a complete resection is not possible. New technologies such as virtual chromoendoscopy are emerging as potential tools in CRC screening. Patients with IBD at increased risk for developing CRC should undergo surveillance colonoscopy using new approaches and techniques.

Keywords: Chromoendoscopy; Colonoscopy; Colorectal cancer screening; Crohn’s disease; Inflammatory bowel disease; Ulcerative colitis.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: All the Authors have no conflict of interest related to the manuscript.

References

    1. Laine L, Kaltenbach T, Barkun A, McQuaid KR, Subramanian V, Soetikno R SCENIC Guideline Development Panel. SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. Gastroenterology. 2015;148:639–651.e28. - PubMed
    1. Farraye FA, Odze RD, Eaden J, Itzkowitz SH. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010;138:746–774, 774.e1-4; quiz e12-13. - PubMed
    1. Riddell RH, Goldman H, Ransohoff DF, Appelman HD, Fenoglio CM, Haggitt RC, Ahren C, Correa P, Hamilton SR, Morson BC. Dysplasia in inflammatory bowel disease: Standardized classification with provisional clinical applications. Hum Pathol. 1983;14:931–968. - PubMed
    1. Itzkowitz SH, Harpaz N. Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. Gastroenterology. 2004;126:1634–1648. - PubMed
    1. Feakins RM British Society of Gastroenterology. Inflammatory bowel disease biopsies: Updated British Society of Gastroenterology reporting guidelines. J Clin Pathol. 2013;66:1005–1026. - PubMed

MeSH terms